Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Breaking Updates in Hematological-Oncology
The American Society of Hematology (ASH) 2021 Annual Meeting and Exposition was held in Atlanta on the 11-14 December. ASH has successfully honed the hybrid model and showcased outstanding leaps in understanding and treatment in 2021, across malignancies. Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.ASH 2021
It's been a jam-packed morning here in Glasgow at #IMS26! 🏴
From new data to clinical practice insights, we've covered a lot of ground in #MultipleMyeloma with experts including @DrOlaLandgren, @YiLinMDPhD, @MyMKaiser, and Elena Zamagni.
🎥 Stay tuned on
It's our final day at #IMS26! 🏴 📣
Thank you to Luciano Costa (@End_myeloma) for stopping by just now to share insights from the MajesTEC-3 post hoc analysis, comparing tec-dara with dara-based triplets in R/R #MultipleMyeloma.
#Myeloma #MMsm #TrialUpdates #CTSM
Lovely to catch up with @Mohty_EBMT just now at #IMS26! 🏴
🎥 He shared key highlights from the meeting so far. Watch out for his insights, coming soon to https://VJHemOnc.com!
#MMsm #MultipleMyeloma #Myeloma @Myeloma_Society
We're rounding out day 2 of #IMS26 by speaking with @FrancescoMaura4!
He covered topics including genomics and epigenetics, t(11;14) in treatment-naïve GPRC5D-negative #MultipleMyeloma, and the sequencing of CELMoDs. 🧬 🎥
#MMsm @Myeloma_Society
It was great speaking with @DrRakeshPopat this afternoon at #IMS26 to discuss the interim results from the ProMMise D study and gain insights into the CEVOLUTION trial.
Full interview coming soon to https://VJHemOnc.com 📽️ 👀
#MMsm #MultipleMyeloma #Myeloma @Myeloma_Society
ASH 2021
Breaking Updates in Hematological-Oncology
The American Society of Hematology (ASH) 2021 Annual Meeting and Exposition was held in Atlanta on the 11-14 December. ASH has successfully honed the hybrid model and showcased outstanding leaps in understanding and treatment in 2021, across malignancies. Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.It's been a jam-packed morning here in Glasgow at #IMS26! 🏴
From new data to clinical practice insights, we've covered a lot of ground in #MultipleMyeloma with experts including @DrOlaLandgren, @YiLinMDPhD, @MyMKaiser, and Elena Zamagni.
🎥 Stay tuned on
It's our final day at #IMS26! 🏴 📣
Thank you to Luciano Costa (@End_myeloma) for stopping by just now to share insights from the MajesTEC-3 post hoc analysis, comparing tec-dara with dara-based triplets in R/R #MultipleMyeloma.
#Myeloma #MMsm #TrialUpdates #CTSM
Lovely to catch up with @Mohty_EBMT just now at #IMS26! 🏴
🎥 He shared key highlights from the meeting so far. Watch out for his insights, coming soon to https://VJHemOnc.com!
#MMsm #MultipleMyeloma #Myeloma @Myeloma_Society
We're rounding out day 2 of #IMS26 by speaking with @FrancescoMaura4!
He covered topics including genomics and epigenetics, t(11;14) in treatment-naïve GPRC5D-negative #MultipleMyeloma, and the sequencing of CELMoDs. 🧬 🎥
#MMsm @Myeloma_Society
It was great speaking with @DrRakeshPopat this afternoon at #IMS26 to discuss the interim results from the ProMMise D study and gain insights into the CEVOLUTION trial.
Full interview coming soon to https://VJHemOnc.com 📽️ 👀
#MMsm #MultipleMyeloma #Myeloma @Myeloma_Society
Popular videos
View all
Press Briefings
View all
Multiple Myeloma
View all
Lymphoma
View all
Acute Myeloid Leukemia
View all
Acute Lymphoblastic Leukemia
View all
Myelodysplastic Syndromes
View all
Chronic Lymphocytic Leukemia
View all
Myeloproliferative Neoplasms
View all
CAR-T & Cellular Therapy News
View all
